OncoTargets and Therapy (Mar 2020)
Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma
Abstract
Shorook Na’ara,1,2 Abhishek Mukherjee,3 Salem Billan,2,4 Ziv Gil1,2 1The Laboratory for Applied Cancer Research, Department of Otolaryngology Head and Neck Surgery, Technion-Israel Institute of Technology, Rambam Healthcare Campus, Haifa, Israel; 2The Head and Neck Center, Rambam Healthcare Campus, Clinical Research Institute at Rambam, Rappaport Institute of Medicine and Research, Technion-Israel Institute of Technology, Haifa, Israel; 3Department of Genetics and Developmental Biology, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; 4The Oncology Institute, Rambam Health Care Campus, Haifa, IsraelCorrespondence: Shorook Na’araDepartment of Otolaryngology, Head and Neck Surgery, Rambam Health Care Campus, Haifa, IsraelEmail [email protected]: Sinonasal mucosal melanoma (SNMM) is a rare tumor, comprising less than 10% of sinonasal malignancies. SNMM most frequently occurs in the nasal cavity (70%) and maxillary sinus (14%), typically as black patches. Overall, SNMM harbors a very poor prognosis; 5-year survival is less than 30%. Nasal cavity tumors confer a better prognosis than sinus melanoma. The primary management for SNMM is surgery, when feasible, followed by adjuvant radiotherapy. Recent studies suggest that immunotherapy may confer survival benefit to patients with advanced disease. The multidisciplinary team approach has been shown to optimize treatment, reduce costs, and minimize adverse events, while maximizing the chances for cure.Keywords: mucosal melanoma, head and neck, multidisciplinary
